Evidence map›Paper›PMID 20716633›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2010

Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study.

H-H Sherry Chow, Linda L Garland, Chiu-Hsieh Hsu, Donna R Vining, Wade M Chew, Jessica A Miller, Marjorie Perloff, James A Crowell, David S Alberts

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 3 pooled it
7.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 3 syntheses or guidelines pooled it, 320 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Resveratrol for adults with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. In Vitro and In Vivo Effects of Resveratrol on Rat Hepatic CYP1A2.Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

H-H Sherry ChowArizona Cancer Center, The University of Arizona, Tucson, AZ 85724, USA. schow@azcc.arizona.edu
Linda L Garland
Chiu-Hsieh Hsu
Donna R Vining
Wade M Chew
Jessica A Miller
Marjorie Perloff
James A Crowell
David S Alberts
University of Arizona · USNational Cancer Institute · US

Funding

PHASE I AND II CLINICAL TRIALS OF CANCER CHEMOPREVENTIVE AGENTS-261035-261035158N01CN035158 · CN · UNIVERSITY OF ARIZONA · PI ALBERTS, DAVID S · 2004 to 2006
–
NCI NIH HHS N01 CN035158
6 · The paper itself

Abstract

Resveratrol has been shown to exhibit cancer-preventive activities in preclinical studies. We conducted a clinical study to determine the effect of pharmacologic doses of resveratrol on drug- and carcinogen-metabolizing enzymes. Forty-two healthy volunteers underwent baseline assessment of cytochrome P450 (CYP) and phase II detoxification enzymes. CYP1A2, CYP2D6, CYP2C9, and CYP3A4 enzyme activities were measured by the metabolism of caffeine, dextromethorphan, losartan, and buspirone, respectively. Blood lymphocyte glutathione S-transferase (GST) activity and GST-pi level and serum total and direct bilirubin, a surrogate for UDP-glucuronosyl transferase (UGT) 1A1 activity, were measured to assess phase II enzymes. After the baseline evaluation, study participants took 1 g of resveratrol once daily for 4 weeks. Enzyme assessment was repeated upon intervention completion. Resveratrol intervention was found to inhibit the phenotypic indices of CYP3A4, CYP2D6, and CYP2C9 and to induce the phenotypic index of 1A2. Overall, GST and UGT1A1 activities were minimally affected by the intervention, although an induction of GST-pi level and UGT1A1 activity was observed in individuals with low baseline enzyme level/activity. We conclude that resveratrol can modulate enzyme systems involved in carcinogen activation and detoxification, which may be one mechanism by which resveratrol inhibits carcinogenesis. However, pharmacologic doses of resveratrol could potentially lead to increased adverse drug reactions or altered drug efficacy due to inhibition or induction of certain CYPs. Further clinical development of resveratrol for cancer prevention should consider evaluation of lower doses of resveratrol to minimize adverse metabolic drug interactions.

Indexed as

AdultAntineoplastic Agents, PhytogenicCarcinogensChromatography, High Pressure LiquidCytochrome P-450 Enzyme SystemEnzyme ActivationFemaleHealthHealthy VolunteersHumansInactivation, MetabolicMaleMiddle AgedPharmaceutical PreparationsResveratrolStilbenesAntineoplastic Agents, PhytogenicCarcinogensCytochrome P-450 Enzyme SystemPharmaceutical PreparationsResveratrolStilbenes

Identifiers

PMID20716633
PMCPMC2933312
OpenAlexW2158735110

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.